Alkaloid marked 9% growth in consolidated export, 7% growth in consolidated net profit, investments of MKD 357.3 million and 51 new employments in the period January - March 2018

02.05.2018

Alkaloid marked 9% growth in consolidated export, 7% growth in consolidated net profit, investments of MKD 357.3 million and 51 new employments in the period January - March 2018

Alkaloid AD Skopje achieved positive financial results in the period January-March 2018 - shows the unaudited standalone and unaudited consolidated Income Statement.

According to the unaudited standalone Income Statement, in the period January- March the sales reached the amount of MKD 1,845,629,963 - 4% up on the same period last year. Earnings before interest, taxes, depreciation and amortization (EBITDA), which amount to MKD 365,029,832 marked an increase of roughly 7%, whereas the net profit amounting to MKD 215,295,378 rose by 6%.

In the period January – March the total consolidated sales reached MKD 2,458,001,587 – an increase of 5% compared to the same period last year. Consolidated sales in the domestic market are at the same level, while the total consolidated export of the company increased by 9%. Out of the total consolidated sales, 36% were realized in the domestic market, while the foreign markets account for 64%. The breakdown by region shows that the countries of South-East Europe account for 34% of the sales, Russia and CIS – 8%, 20% of the sales were realized in the countries from Western Europe (EU and EFTA), while the other markets account for 2% of the total consolidated sales. Noticeable rise was seen in USA reaching sales of MKD 49,862,281 - increased by 2.7 times and Hungary with sales of MKD 29,834,403 – increased by 10 times compared to the same period last year. Growth in sales was also marked in the following export markets: Poland - 353%, Ukraine - 123%, Kosovo - 38%, Czech Republic - 31%, Serbia - 28%, etc.

The breakdown of total consolidated sales by group of products shows that the best sellers are the products from the segment Pharmaceuticals – 85%, with OTC products accounting for 19%, cardiovascular products - 16%, antibiotics - 17%, neurological products – 13% etc. The Chemistry Cosmetics Botanicals segment accounts for 15% of the total consolidated sales, or more precisely Chemistry – 3%, Cosmetics – 8% and Botanicals – 4%.

Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA), which reached MKD 414,007,823 saw an increase of 6%, whereas the net consolidated profit amounting to MKD 246,800,792 went up by 7%.

The total investments in non-current assets for the period January – March 2018 amounted to MKD 357,342,100 - increased by almost 3 times compared to 2017.

In the period January – March 2018 Alkaloid recruited 51 new employees in the Republic of Macedonia.